Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The inaugural Doug Altman scholarship will be offered to an LMIC (lower-to-middle-income country) applicant or a student.

Now in its 18th year, the Centre for Statistics in Medicine's (CSM) Randomised Controlled Trials Course provides a thorough grounding in the principles and practice of randomised controlled trials (RCTs) for evaluating healthcare interventions.

For the first time in 2020, NDORMS is offering a sponsored place for an applicant from an LMIC (lower-to-middle-income country) or a student. The Doug Altman scholarship has been established in memory of course founder Professor Doug Altman, who was an advocate for transparency in scientific research and dedicated his 40-year career to developing essential tools for better design, analysis, clarity, and reporting of clinical research.

"Back in the early noughties, I was invited to a meeting with Doug Altman, then Director of the CSM, and we decided to create a short course" said Associate Professor Ed Juszczak, Director of the National Perinatal Epidemiology Unit Clinical Trials Unit and co-founder of the RCT Course. "We wanted to share our knowledge and experiences of every aspect of a clinical trial, aiming the course at those planning an RCT or actively running one, marrying the statistics with logistics and rationale, making it understandable and accessible for all. The course has run annually in Oxford since 2003 with 631 participants to date."

The sponsorship covers the full cost of the course fee and accommodation at Merton College for the duration of the five-day course, which will run from Monday 21 to Friday 25 September 2020.

Associate Professor Jonathan Cook, Course Lead said: "The course brings together a highly experienced interdisciplinary faculty of clinicians, statisticians, trialists and trial managers, and attracts participants from a very diverse range of sectors from health professionals and trial staff, through to funders and journal editors. I'm looking forward to another wonderfully stimulating and enjoyable week, learning and thinking about randomised trials in the inspiring surroundings of Merton College."

If you would you like to be considered for the sponsored place, please contact Jacqueline Wright on rct.course@csm.ox.ac.uk for more information and to request an application form.

Similar stories

New centre aims to help companies conduct more efficient trials

Botnar Main Trials

A new clinical therapeutics centre has been set up by the University of Oxford to help life sciences companies identify interventions that have the greatest potential to deliver patient benefit, and so bring down the cost of early phase clinical trials.

Cognitive–behavioural therapy consistently improves quality of life

Main Rehabilitation and self-management Research

A meta-review of the available research into cognitive behavioural therapy reveals it consistently improves health-related quality of life across different medical conditions and demographic populations.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

Main Research

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Versus Arthritis Foundation Fellowship awarded to Dr Kristina Zec

Awards Main

Dr Kristina Zec has been awarded a Versus Arthritis Foundation Fellowship to investigate the role of products of lipid oxidation produced by synovial macrophages in triggering articular inflammation.

Study reveals the safety of bisphosphonates in chronic kidney disease

Main

The results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.

WHiTE Four trial results published

Hip Main OCTRU Orthopaedics and trauma Research

The results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.